To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa isolated from bloodstream infections from Qatar
Örebro University, School of Science and Technology. Department of Pathology and Laboratory Medicine, Division of Microbiology, Hamad Medical Corporation, Doha, Qatar. (The Life Science Centre)ORCID iD: 0000-0002-6186-7770
Department of Pathology and Laboratory Medicine, Division of Microbiology, Hamad Medical Corporation, Doha, Qatar.
Department of Medicine, Division of Infectious Diseases, Hamad Medical Corporation, Doha, Qatar; Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar.
Department of Medicine, Division of Infectious Diseases, Hamad Medical Corporation, Doha, Qatar; Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar.
Show others and affiliations
2021 (English)In: Annals of Medicine, ISSN 0785-3890, E-ISSN 1365-2060, Vol. 53, no 1, p. 2345-2353Article in journal (Refereed) Published
Abstract [en]

Background: Bloodstream infections (BSIs) caused by multidrug-resistant (MDR)-Pseudomonas aeruginosa are associated with poor clinical outcomes, at least partly due to delayed appropriate antimicrobial therapy. The characteristics of MDR-P. aeruginosa bloodstream isolates have not been evaluated in Qatar. Our study aimed to examine in vitro susceptibility, clinical and molecular characteristics, and mechanisms of resistance of MDR-P. aeruginosa bloodstream isolates from Qatar.

Materials and methods: We included all MDR-P. aeruginosa isolated from blood cultures taken between October 2014 and September 2017. Blood cultures were processed using BD BACTEC™ FX automated system. BD Phoenix™ was used for identification, Liofilchem® MIC Test Strips for MIC determination. Whole-genome sequencing was performed using the Illumina-HiSeq-2000.

Results: Out of 362 P. aeruginosa bloodstream isolates, 16 (4.4%) were MDR. The median patient age was 55 years (range 43-81) and all patients presented with septic shock. Most patients received meropenem (12/16) and/or colistin (10/16). Clinical response was achieved in eight patients, and five patients died within 30-days. MDR-P. aeruginosa isolates belonged to 13 different sequence types. All isolates were non-susceptible to cefepime and ciprofloxacin. The most active agents were colistin (16/16) and aztreonam (10/16). Seven isolates produced blaVIM, and four possessed genes encoding extended-spectrum β-lactamases. Aminoglycoside modifying enzymes were present in 15/16, transferable qnr-mediated quinolone resistance gene was detected in 3/16, and the novel ciprofloxacin modifying enzyme CrpP-encoding gene in one isolate.

Conclusion: MDR-P. aeruginosa BSIs are relatively uncommon in Qatar but are highly resistant, harbour multiple resistance genes, and are commonly associated with unfavourable clinical outcomes. Colistin was the only agent with consistent activity against the study isolates.Key messagesMDR-P. aeruginosa constituted <5% of P. aeruginosa blood isolates over three years.Typical risk factors for MDR infections were highly prevalent in the study population and overall clinical outcomes are consistent with those previously reported.Colistin was the only agent with consistent antibacterial activity against the study isolates.

Place, publisher, year, edition, pages
Taylor & Francis, 2021. Vol. 53, no 1, p. 2345-2353
Keywords [en]
Bacteraemia, MDR, Pseudomonas aeruginosa, Qatar
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-95896DOI: 10.1080/07853890.2021.2012588ISI: 000728376500001PubMedID: 34882052Scopus ID: 2-s2.0-85120968888OAI: oai:DiVA.org:oru-95896DiVA, id: diva2:1619281
Funder
Swedish Research Council Formas, 219-2014-837
Note

Funding agencies:

Qatar National Library

Medical Research Centre at Hamad Medical Corporation, Doha, Qatar IRGC-01-51-033

National Priorities Research Program (NPRP) from Qatar National Research Fund (a member of Qatar Foundation) NPRP12S-0219-190109 

Available from: 2021-12-13 Created: 2021-12-13 Last updated: 2021-12-21Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Sid Ahmed, MazenSöderquist, BoJass, Jana

Search in DiVA

By author/editor
Sid Ahmed, MazenSöderquist, BoJass, Jana
By organisation
School of Science and TechnologySchool of Medical Sciences
In the same journal
Annals of Medicine
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 46 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf